Chapter 3.3 Depression and effects of antidepressant drugs on the stress systems

Techniques in the Behavioral and Neural Sciences

Volumn 15, Issue PART 2, 2005, Pages 273-286

  Modell, Sieglinde ^a   Holsboer, Florian ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956658103     PISSN: 09210709     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0921-0709(05)80059-8     Document Type: Chapter

References (87)

1. Adam K., Oswald I., and Shapiro C. Effects of loprazolam and of triazolam on sleep and overnight urinary cortisol. Psychopharmacology 82 (1984) 389-394
2. Arana G.W., Baldessarini R.J., and Ornsteen M. The Dexamethasone suppression test for diagnosis and prognosis in psychiatry. Arch. Gen. Psychiatry 42 (1991) 1193-1204
3. Barden N., Stec I., Montkowski A., Holsboer F., and Reul J.M.H.M. Endocrine profile and neuroendocrine challenge tests in transgenic mice expressing antisense RNA against the glucocorticoid receptor. Neuroendocrinology 66 (1997) 200-212
4. Bleuler M. The internal secretions and the nervous system. (Nervous and Mental Disease Monograph Series, No. 30) (1919), Nervous and Mental Disease Publ. Comp., New York
5. Brady L.S., Gold P.W., Herkenham M., Lynn A.B., and Whitfield Jr. H.J. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res. 572 (1992) 117-125
6. Bschor T., Adli M., Baethge C., Eichmann U., Ising M., Uhr M., Modell S., Künzel H., Müller-Oerlinghausen B., and Bauer M. Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. Neuropsychopharmacology 27 (2002) 470-478
7. Buwalda B., de Boer S.F., Schmidt E.D., Felszeghy K., Nyakas C., Sgoifo A., van der Vegt B.J., Tilders F.J.H., Bohus B., and Koolhaas J.M. Long-lasting deficient Dexamethasone suppression of hypothalamic-pituitary-adrenocortical activation following peripheral CRF challenge in socially defeated rats. J. Neuroendocrinol. 11 (1999) 513-520
8. Christensen P., Lolk A., Gram L.F., Kragh-Sorensen P., Pedersen O.L., and Nielsen S. Cortisol and treatment of depression: predictive values of spontaneous and suppressed cortisol levels and course of spontaneous plasma cortisol. Psychopharmacology 97 (1989) 471-475
9. Craddock N.J. Genetics of bipolar disorder. J. Med. Genet. 36 (1999) 585-594
10. De Bellis M.D., Gold P.W., Geracioti Jr. T.D., Listwalk S.J., and Kling M.A. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am. J. Psychiatry 150 (1993) 656-657
11. De Beurs E., Beekman A., Geerlings S., Deeg D., Van Dyck R., and Van Tilburg W. On becoming depressed or anxious in late life: similar vulnerability factors but different effects of stressful life events. Br. J. Psychiatry 179 (2001) 426-431
12. Delbende C., Contesse V., Mocaer E., Kamoun A., and Vaudry H. The novel antidepressant, tianeptine, reduces stress-evoked stimulation of the hypothalamo-pituitary-adrenal axis. Eur. J. Pharmacol. 202 (1991) 391-396
13. Deuschle M., Schmider J., Weber B., Standhardt H., Korner A., Lammers C.H., Schweiger U., Hartmann A., and Heuser I. Pulse-dosing and conventional application of doxepin: effects on psychopathology and hypothalamus-pituitary-adrenal (HPA) system. J. Clin. Psychopharmacol. 17 (1997) 156-160
14. Dodt C., Kern W., Fehm H.L., and Born J. Antimineralocorticoid canrenoate enhances secretory activity of the hypothalamus-pituitary-adrenocortical (HPA) axis in humans. Neuroendocrinology 58 (1993) 570-574
15. Erkut Z.A., Pool C., and Swaab D.F. Glucocorticoids suppress corticotropin-releasing hormone and vasopressin expression in human hypothalamic neurons. J. Clin. Endocrinol. Metab. 83 (1998) 2066-2073
16. Frank E.T.M. Natural history and preventive treatment of recurrent mood disorders. Annu. Rev. Med. 50 (1999) 453-468
17. Freedman R., Coon H., Myles-Worsely M., Orr-Urtreger A., Olinca A., Davis A., Polymeropoulos M., Holik J., Hopkins J., Hoff M., Rosenthal J., Waldo M.C., Reimherr F., Wender P., Yaw J., Young D.A., Breese C.R., Adams C., Patterson D., Adler L.E., Kruglyak L., Leonard S., and Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. USA 94 (1997) 587-592
18. Glassmann A.H., and Shapiro P.A. Depression and the course of coronary disease. Am. J. Psychiatry 155 (1998) 4-11
19. Gold P.W., Chronsos G., Kellner C., Post R., Roy A., Angerinos P., Schulte H., Oldfield E., and Loriaux D.L. Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am. J. Psychiatry 141 (1984) 619-627
20. Gram L.F., Christensen L., Kristensen C.B., and Kragh-Sorensen P. Suppression of plasma cortisol after oral administration of oxazepam in man. Br. J. Clin. Pharmacol. 17 (1984) 176-178
21. Greden J.F., Gardner R., King D., Grunhaus L., Carroll B.J., and Kronfol Z. Dexamethasone suppression tests in antidepressant treatment of melancholia - the process of normalization and test-retest reproductability. Arch. Gen. Psychiatry 40 (1983) 493-500
22. Heim C., Newport D.J., Heit S., Graham Y.P., Wilcox M., Bonsall R., Miller A.H., and Nemeroff C.B. Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA 284 (2000) 592-597
23. Heuser I., Yassouridis A., and Holsboer F. The combined Dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J. Psychiat. Res. 28 (1994) 341-356
24. Heuser I.J.E., Schweiger U., Gotthardt U., Schmider J., Lammers C.H., Dettling M., Yassouridis A., and Holsboer F. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am. J. Psychiatry 153 (1996) 93-99
25. Holsboer F. Prediction of clinical course by Dexamethasone suppression test (DST) response in depressed patients - physiological and clinical construct validity of the DST. Pharmacopsychiatry 16 (1982) 186-191
26. Holsboer F., and Barden N. Antidepressants and HPA regulation. Endocrinol. Rev. 17 (1996) 187-203
27. Holsboer F., Liebl R., and Hofschuster E. Repeated dexamethasone suppression test during depressive illness. Normalization of test result compared with clinical improvement. J. Affect. Disord. 4 (1982) 93-101
28. Holsboer F., Gerken A., Stalla G.K., and Müller O.A. Blunted corticotropin- and normal corticol response to human corticotropin-releasing factor in depression. N. Engl. J. Med. 311 (1984) 1127
29. Holsboer F., von Bardeleben U., Wiedemann K., Müller O.A., and Stalla G.K. Serial assessment of corticotropin-releasing hormone response after Dexamethasone in depression - implications for pathophysiology of DST nonsuppression. Biol. Psychiatry 22 (1987) 228-234
30. Holsboer F., Lauer C.J., Schreiber W., and Krieg J.-C. Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology 62 (1995) 340-347
31. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23 (2000) 477-501
32. Horwath E., Johnson J., Weissman M., and Hornig C. The validity of major depression with atypical features based on a community study. J. Affect. Disord. 2 (1992) 117-125
33. Karanth S., Linthorst A.C.E., Stalla G.K., Barden N., Holsboer F., and Reul J.M.H.M. Hypothalamic-pituitary-adrenocortical axis changes in a transgenic mouse with impaired glucocorticoid receptor function. Endocrinology 138 (1997) 3476-3485
34. Keck M.E., Wigger A., Welt T., Müller M.B., Gesing A., Reul J.H.M.H., Holsboer F., Landgraf R., and Neumann I.D. Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders. Neuropsychopharmacology 26 (2002) 94-105
35. online publication: 25 July 2002 at http://www.acnp.org/citations/Npp072502357. Keck M., Welt T., Müller M.B., Uhr M., Ohl F., Wigger A., Toschi N., Holsboer F., and Landgraf R. Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology (2002)
36. Kendler K.S., Karkowski L.M., and Prescott C.A. Causal relationship between stressful life events and the onset of major depression. Am. J. Psychiatry 156 (1999) 837-841
37. Kendler K.S., Thornton L.M., and Prescott C.A. Gender differences in the rates of exposure to stressful life events and sensitivity to their depressogenic effects. Am. J. Psychiatry 158 (2001) 587-593
38. Kessler R.C., Mcgonagle K.A., Swartz M., Blazer D.G., and Nelson C.B. Sex and depression in the National Comorbidity Survey, I: lifetime prevalence, chronicity and recurrence. J. Affect. Disord. 29 (1993) 85-96
39. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., Wittchen H.U., and Kendler K. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorder in the United States. Arch. Gen. Psychiatry 51 (1994) 8-19
40. Kirschbaum C., Wüst S., Faig H.-G., and Hellhammer D.H. Heritability of cortisol responses to human corticotropin-releasing hormone, ergometry, and psychological stress in humans. J. Clin. Endocrinol. Metab. 75 (1992) 1526-1530
41. Ladd C.O., Stowe Z.N., and Plotsky P.M. Reversal of neonatal maternal separation phenotype by reboxetine. Soc. Neurosci. Abstr. 2 (1999) 1456
42. Landgraf R. Neuropeptides and anxiety-related behaviour. Endocr. J. 48 (2001) 517-533
43. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Muller C.R., Hamer D.H., and Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274 (1996) 1527-1531
44. Linthorst A.C.E., Flachskamm C., Barden N., Holsboer F., and Reul J.M.H.M. Glucocorticoid receptor impairment alters CNS responses to a psychological stressor: an in vitro microdialysis study in transgenic mice. Eur. J. Neurosci. 12 (2000) 283-291
45. Lloyd C. Life events and depressive disorder reviewed: 1. Events as predisposing factors. Arch. Gen. Psychiatry 37 (1980) 529-535
46. Maxwell J.D., Boyle J.A., Greig W.R., and Buchanan W.W. Plasma corticosteroids in healthy twin pairs. J. Med. Genet. 6 (1969) 294-297
47. McGuffin P., and Katz R. The genetics of depression and manic-depressive disorder. Br. J. Psychiatry 155 (1989) 294-304
48. Meijer O.C., de Lange E.C.M., Breimer D.D., de Boer A.G., Workel J.O., and de Kloet E.R. Penetration of Dexamethasone into brain glucocorticoid targets is enhanced in mdrlAP-glycoprotein knockout mice. Endocrinology 139 (1998) 1789-1793
49. Meikle A.W., Stringham J.D., Woodward M.G., and Bishop D.T. Heritability of variation of plasma cortisol levels. Metabolism 37 (1988) 514-517
50. Meloni R., Leboyer M., Bellivier F., Barbe B., Samolyk D., Allilaire J.F., and Mallet J. Association of manic-depressive illness with tyrosine hydroxylase microsatellite marker. Lancet 345 (1996) 932
51. Michelson D., Galliven E., Hill L., Demitrack M., Chrousos G., and Gold P. Chronic imipramine is associated with diminished hypothalamic-pituitary-adrenal axis responsivity in healthy humans. J. Clin. Endocrinol. Metab. 82 (1997) 2601-2606
52. Michaelson D., Amsterdam J., Apter J., Fava M., Londborg P., Tamura R., and Pagh L. Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment. Psychoneuroendocrinology 25 (2000) 169-177
53. Modell S., Yassouridis A., Huber J., and Holsboer F. Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology 65 (1997) 216-222
54. Modell S., Lauer C.J., Schreiber W., Huber J., Krieg J.-C., and Holsboer F. Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology 18 (1998) 253-262
55. Montkowski A., Barden N., Wotjak C., Stec I., Ganster J., Meaney M., Engelmann M., Reul J.H.M.H., Landgraf R., and Holsboer F. Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. J. Neuroendocrinol. 7 (1995) 841-845
56. Murray C.J.L., and Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 349 (1997) 1498-1504
57. Nickel T., Sonntag A., Schill J., Zobel A.W., Ackl N., Brunnauer A., Murck H., Ising M., Yassouridis A., Steiger A., Zihl J., and Holsboer F. Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J. Clin. Psychopharmacol 23 (2003) 155-168
58. Paykel E., Myers J.K., Dienelt M.N., Kleman G.L., Lindenthal J.J., and Pepper M.P. Life events and depression. Arch. Gen. Psychiatry 21 (1969) 753-760
59. Paykel E.S. Life events, social support and depression. Acta Psychiatr. Scand. Suppl. 377 (1994) 50-58
60. Peiffer A., Veilleux S., and Barden N. Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain. Psychoneuroendocrinology 16 (1991) 505-515
61. Pepin M.C., Pothier F., and Barden N. Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene. Nature 355 (1992) 725-728
62. Post R.M. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am. J. Psychiatry 149 (1992) 999-1010
63. Przegalinski E., and Budziszewska B. The effect of long-term treatment with antidepressant drugs on the hippocampal mineralocorticoid and glucocorticoid receptors in rats. Neurosci. Lett. 161 (1993) 215-218
64. Purba J.S., Hoogendijk W.J.G., Hofman M.A., and Swaab D.F. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch. Gen. Psychiatry 53 (1996) 137-143
65. Raadsheer F.C., Hoogendijk W.J.G., Stam F.C., Tilders F.H.J., and Swaab D.F. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60 (1994) 433-436
66. Ratka A., Sutanto W., Bloemers M., and de Kloet E.R. On the role of brain mineralocorticoid (type-I) and glucocorticoid (type-II) receptors in neuroendocrine regulation. Neuroendocrinology 50 (1989) 117-123
67. Reul J.H.M.H., Stec I., Söder M., and Holsboer F. Chronic treatment of rats with the antidepressant amitripty-line attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 133 (1993) 312-320
68. Reul J.H.M.H., Labeur M.S., Grigoriadis D.E., de Souza E.B., and Holsboer F. Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 60 (1994) 509-519
69. Reul J.M.H.M., Probst J.C., Skutella T., Hirschmann M., Stec I.S., Montkowski A., Landgraf R., and Holsboer F. Increased stress-induced adrenocorticotropin response after long-term intracerebroventricular treatment of rats with antisense mineralocorticoid receptor oligodeoxynucleotides. Neuroendocrinology 65 (1997) 189-199
70. Reul J.M.H.M., Gesing A., Droste S., Stec I.S.M., Weber A., Bachmann C., Bilang-Bleuel A., Holsboer F., and Linthorst A.C.E. The brain mineralocorticoid receptor: greedy for ligand, mysterious in function. Eur. J. Pharmacol. 405 (2000) 235-249
71. Saß H., Wittchen H.-U., and Zaudig M. Diagnostisches und Statistisches Manual Psychischer Störungen DSM-IV. Hogrefe Verlag für Psychologie, Göttingen, Bern, Toronto, Seattle (1998)
72. Schulkin J., Gold P.W., and McEwen B.S. Induction of corticotropin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety and allostatic load. Psychoneuroendocrinology 23 (1998) 219-243
73. Sillaber I., Montkowski A., Landgraf R., Barden N., Holsboer F., and Spanagel R. Enhanced morphine-induced behavioural effects and dopamine release in the nucleus accumbens in a transgenic mouse model of impaired glucocorticoid (type II) receptor function: Influence of long-term treatment with the antidepressant moclobemide. Neuroscience 85 (1998) 415-425
74. Skelton K.H., Nemeroff C.B., Knight D.L., and Owens M.J. Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems. J. Neurosci. 20 (2000) 1240-1248
75. Smith G.W., Aubry J.-M., Dellu F., Contarino A., Bilezikjian L.M., Gold L.H., Hauser C., Bentley C.A., Sawchenko P.E., Koob G.F., Vale W., and Lee K.-F. Corticotropin-releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20 (1998) 1093-1103
76. Spencer R.L., Kim P.J., Kalman B.A., and Cole M.A. Evidence for mineralocorticoid receptor facilitation of glucocorticoid receptor-dependent regulation of hypothalamic-pituitary-adrenal axis activity. Endocrinology 139 (1998) 2718-2726
77. Stec I., Barden N., Reul J.H.M.H., and Holsboer F. Dexamethasone nonsuppression in transgenic mice expressing antisense RNA to the glucocorticoid receptor. J. Psychiatr. Res. 28 (1994) 1-5
78. Steckler T., Weis C., Sauvage M., Mederer A., and Holsboer F. Disrupted allocentric but preserved egocentric spatial learning in transgenic mice with impaired glucocorticoid receptor function. Behav. Brain Res. 100 (1999) 77-89
79. Steckler T., Sauvage M., and Holsboer F. Glucocorticoid receptor impairment enhances impulsive responding in transgenic mice performing on a simultaneous visual discrimination task. Eur. J. Neurosci. 12 (2000) 2559-2569
80. Steckler T., Rammes G., Sauvage M., van Gaalen M.M., Weis C., Zieglgänsberger W., and Holsboer F. Effects of the monoamine oxidase A inhibitor moclobemide on hippocampal plasticity in GR-impaired transgenic mice. J. Psychiatric Res. 35 (2000) 29-42
81. Von Bardeleben U., and Holsboer F. Cortisol response to a combined Dexamethasone-hCRH challenge in patients with depression. J. Neuroendocrinol. 1 (1989) 485-488
82. Von Bardeleben U., Holsboer F., Stalla G.K., and Müller O.A. Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Sci. 37 (1985) 1613-1619
83. Wender P.H., Kety S.S., Rosenthal D., Schulsinger F., Ortmann J., and Lunde I. Psychological disorders in the biological and adoptive relatives of individuals with affective disorders. Arch. Gen. Psychiatry 43 (1986) 923-929
84. Young E.A., Lopez J.F., Murphy-Weinberg V., Watson S.J., and Akil H. The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans. J. Clin. Endocrinol. Metab. 83 (1998) 3339-3345
85. Zisook S., and Downs N.S. Death, dying and bereavement. In: Sadock B.J., and Kaplan V.A. (Eds). Comprehensive Textbook of Psychiatry. 7th Ed. (2000), Lippincott Williams & Wilkins, New York 1963-1981
86. Zobel A.W., Nickel T., Künzel H.E., Ackl N., Sonntag A., Ising M., and Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatric. Res. 34 (2000) 171-181
87. Zobel A.W., Nickel T., Sonntag A., Uhr M., Holsboer F., and Ising M. Cortisol response in the combined DEX/CRH test as a predictor of relapse in patients with remitted depression: a prospective study. J. Psychiatric. Res. 35 (2001) 83-94